La técnica “parejas de escritura y edición cooperativa” como estrategia didáctica para incentivar la escritura de textos narrativos en los estudiantes de la jornada nocturna de los ciclos quinto y sexto del Colegio Magdalena Ortega de Nariño, en un blog digital.

La reflexión sobre la práctica docente, desarrollada con estudiantes del Ciclo 5 y 6 durante tiempos de pandemia, nos obligaron a modificar nuestra práctica docente. Por tanto, la presente investigación es una propuesta mediada por las tecnologías y los productos académicos de los estudiantes se registran en un blog, permitiendo que dicha herramienta potencie el aprendizaje cooperativo en los estudiantes, además de hacer uso de una técnica llamada “Escritura en parejas y edición cooperativa”, producto de nuestra indagación en estrategias didácticas para incentivar la escritura de textos narrativos, se convirtió en el centro de nuestra práctica docente, esta técnica nos permitió resolver un problema que detectamos en el aula de clase: la escritura. Encontramos que la escritura de los estudiantes es una de las preocupaciones del quehacer docente. Lo constatamos una vez realizado el análisis del diagnóstico, por tanto, el texto narrativo se convierte en nuestro centro de interés y es por esta razón que todas las actividades, como se podrá apreciar, sugieren técnicas para el trabajo en equipo. La propuesta didáctica se muestra por medio de diversas actividades que, de manera gradual, incentivan la escritura de textos narrativos. Seguimos el plan lector para los ciclos quinto y sexto. Esperamos que nuestro ejercicio investigativo se transforme en un estímulo para posteriores trabajos. Escribir “Al alimón”, es decir en parejas, donde se asume una colaboración manifestada en edición cooperativa puede ser una alternativa para incentivar no sólo la escritura de textos narrativos, sino la escritura en general.Universidad Libre - Facultad de Ciencias de la Educación - Licenciatura en Educación Básica con énfasis en Humanidades e IdiomasThe reflection on teaching practice, developed with students from Cycles 5 and 6 during times of pandemic, forced us to modify our teaching practice. Therefore, the present research is a proposal mediated by the technologies and the academic products of the students are registered in a blog, allowing this tool to enhance cooperative learning in students, in addition to making use of a technique called “Writing in pairs and cooperative editing ”, a product of our investigation into didactic strategies to encourage the writing of narrative texts, became the center of our teaching practice. This technique allowed us to solve a problem that we detected in the classroom: writing. We find that students' writing is one of the concerns of the teaching profession. We verify this once the analysis of the diagnosis has been carried out, therefore, the narrative text becomes our center of interest and it is for this reason that all the activities, as you can see, suggest techniques for teamwork. The didactic proposal is shown through various activities that gradually encourage the writing of narrative texts. We follow the reading plan for cycles five and six. We hope that our investigative exercise will become a stimulus for further work. Writing "Al alimón", that is, in pairs, where a collaboration manifested in cooperative publishing is assumed, can be an alternative to encourage not only the writing of narrative texts, but writing in general

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac